PBL continues to supply Erwinase® finished product batches on time.
PBL has made significant investment in resources and devoted effort into ensuring that it manufactures and delivers its life-saving product Erwinase® on schedule.
PBL is proud to have provided support to a team of undergraduate students from Nottingham University who won a Gold Medal at this years international Genetically Engineered Machine (iGEM) competition.
Porton Biopharma Ltd (PBL) has today announced that it has signed a modification to its contract (HHSN272201600045C) with the US National Institute of Health’s National Institute of Allergy and Infectious Diseases (NIAID) to advance a next generation intra-nasal anthrax vaccine into the clinical-trial phase. The contract modification is worth US $4.5 million and follows approval by the US Food and Drug Administration (FDA) of the investigational new drug (IND) application
In this case study, Dr David Gervais, Head of Product and Fermentation Development at Porton Biopharma describes how a non-GMP enzyme manufacturing process has been successfully converted from a native to a recombinant one using bioinformatics and next-generation sequencing (NGS).
Demonstrating PBL’s capability to deliver significant improvements in yield, purity and activity for customer’s products.
Porton Biopharma will be attending the Salisbury Jobs fair in the Guildhall on Tuesday 2nd April. Do come along and see us between 9am and 3pm to find out more about what we do and our exciting range of careers.
PBL will be attending the Innovation in manufacturing through collaboration event in Darlington on Wednesday 27th March, as well as the Bioprocess International Europe conference 2019 conference in Vienna from 2-5th April.
In advance of next week’s National Apprenticeship Week Porton Biopharma Ltd (PBL) is excited to announce that we have recruited our first apprentice, Will Tucker. Joining the company as a full-time employee from the end of February he’ll be enrolled on a five year programme leading to a BSC in applied biology.
PBL has issued a statement regarding the Royalty Bearing Licence Agreement with Jazz Pharmaceuticals for the distribution of Erwinase. The statement can be read here: